Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science

Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice

See more here


Syneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and Retention

Partnership Creates a More Patient-centric Travel Experience, Drives Adherence and Advances Diversity and Inclusion in Clinical Research 

See more here


Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

– IMM-BCP-01 already shown to neutralize all other Centers for Disease Control (CDC) variants of concern in pre-clinical testing

See more here


Renovacor Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

Common stock and warrants of the combined company, renamed Renovacor, Inc., will commence trading on September 3, 2021 on the NYSE under ticker symbols “RCOR” and “RCOR.WS”, respectively.

Gross proceeds from the transaction totaled approximately $95.1 million.

See more here


Phrase Health Awarded Phase 2 NIH Grant To Scale Quality Improvement Platform

The $1.7 million Phase 2 STTR grant expands upon the quality improvement and informatics cloud-based software developed by the company

See more here


ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two
Scientific Journals 

STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers 

Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future therapy for human glioblastoma

Data support the advancement of ImmunoGenesis’ STING-Immune Stimulating Antibody Conjugate (ISAC) in immunologically cold tumors

See more here


Centers for Medicare & Medicaid Services Issues New Code for Encala® 

Code S9432 Will Provide Improved Access for Individuals with Malabsorption and Take Effect October 1, 2021

See more here


Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

Dr. Killeen joins Renovacor from BioMarin where he led the discovery and development of AAV-based gene therapies for inherited cardiac diseases 

See more here


Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam

Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022 

BARDA extends cost-sharing contract to support the development of cefepime-taniborbactam in patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia (HABP/VABP)

Phase 3 clinical trial of cefepime-taniborbactam in patients with HABP/VABP scheduled to begin in 2022

See more here


Wellsheet Granted Patent to Make Electronic Health Records User-Friendly 

Intuitive and Predictive Workflow App for EHR:

• Reduces time spent in the EHR, which reduces physician burnout

Reduces training time and improves productivity

• Increases clinician satisfaction by an order of magnitude

See more here